Central Pacific Bank Trust Division Boosts Holdings in LivaNova PLC (NASDAQ:LIVN)

Central Pacific Bank Trust Division lifted its position in shares of LivaNova PLC (NASDAQ:LIVN) by 21.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,117 shares of the company’s stock after buying an additional 720 shares during the period. Central Pacific Bank Trust Division’s holdings in LivaNova were worth $191,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Driehaus Capital Management LLC raised its stake in shares of LivaNova by 64.7% in the 2nd quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company’s stock valued at $29,824,000 after acquiring an additional 213,749 shares during the period. Perceptive Advisors LLC boosted its stake in shares of LivaNova by 48.5% during the 2nd quarter. Perceptive Advisors LLC now owns 444,000 shares of the company’s stock valued at $24,340,000 after buying an additional 145,000 shares during the last quarter. Great Lakes Advisors LLC bought a new position in LivaNova during the 2nd quarter valued at $16,614,000. Cornercap Investment Counsel Inc. bought a new position in shares of LivaNova during the second quarter worth about $1,103,000. Finally, Allspring Global Investments Holdings LLC grew its position in shares of LivaNova by 3.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 797,284 shares of the company’s stock worth $41,889,000 after acquiring an additional 25,277 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

LIVN has been the topic of several recent research reports. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. The Goldman Sachs Group initiated coverage on LivaNova in a research note on Friday, October 4th. They set a “buy” rating and a $65.00 target price for the company. Needham & Company LLC restated a “buy” rating and set a $75.00 target price on shares of LivaNova in a report on Monday, November 25th. Robert W. Baird lifted their price target on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Finally, Mizuho cut their target price on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, October 31st. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, LivaNova currently has a consensus rating of “Buy” and an average target price of $69.17.

Insiders Place Their Bets

In related news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the sale, the director now directly owns 7,522 shares in the company, valued at approximately $383,546.78. The trade was a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.27% of the company’s stock.

LivaNova Trading Up 1.3 %

Shares of NASDAQ LIVN opened at $47.27 on Friday. The stock has a market cap of $2.57 billion, a price-to-earnings ratio of 112.55 and a beta of 0.98. The business has a 50 day simple moving average of $50.28 and a 200 day simple moving average of $50.61. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. LivaNova PLC has a 52 week low of $43.15 and a 52 week high of $64.47.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.